Similar articles

• Treatment of apathy in Alzheimer's disease with transdermal rivastigmine: report of three cases.

  Granero AL, Lucchetti G. Granero AL, et al. Braz J Psychiatry. 2010 Mar;32(1):94-5. doi: 10.1590/s1516-44462010000100019. Braz J Psychiatry. 2010. PMID: 20339742 No abstract available.
• A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer's disease: a post hoc analysis.

  Farlow MR, Alva G, Meng X, Olin JT. Farlow MR, et al. Curr Med Res Opin. 2010 Feb;26(2):263-9. doi: 10.1185/03007990903434914. Curr Med Res Opin. 2010. PMID: 19929593 Clinical Trial.
• The ACTION study: methodology of a trial to evaluate safety and efficacy of a higher dose rivastigmine transdermal patch in severe Alzheimer's disease.

  Farlow MR, Grossberg G, Gauthier S, Meng X, Olin JT. Farlow MR, et al. Curr Med Res Opin. 2010 Oct;26(10):2441-7. doi: 10.1185/03007995.2010.513849. Curr Med Res Opin. 2010. PMID: 20828359 Clinical Trial.
• A rivastigmine patch for the treatment of Alzheimer's disease and Parkinson's disease dementia.

  Cummings J, Winblad B. Cummings J, et al. Expert Rev Neurother. 2007 Nov;7(11):1457-63. doi: 10.1586/14737175.7.11.1457. Expert Rev Neurother. 2007. PMID: 17997695 Review.
• Rivastigmine transdermal system for the treatment of mild to moderate Alzheimer's disease.

  Grossberg GT, Sadowsky C, Olin JT. Grossberg GT, et al. Int J Clin Pract. 2010 Apr;64(5):651-60. doi: 10.1111/j.1742-1241.2009.02330.x. Epub 2010 Jan 19. Int J Clin Pract. 2010. PMID: 20102418 Review.